Compare FIGR & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIGR | KRYS |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | 602 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 7.8B |
| IPO Year | N/A | 2017 |
| Metric | FIGR | KRYS |
|---|---|---|
| Price | $32.08 | $267.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $53.22 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 3.9M | 225.0K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 6.84 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | $69.23 | $38.74 |
| Revenue Next Year | $24.25 | $32.53 |
| P/E Ratio | $134.36 | ★ $40.09 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $25.01 | $123.03 |
| 52 Week High | $78.00 | $298.30 |
| Indicator | FIGR | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 42.77 | 52.72 |
| Support Level | $25.01 | $254.53 |
| Resistance Level | $34.93 | $297.14 |
| Average True Range (ATR) | 2.23 | 8.03 |
| MACD | 0.08 | 1.17 |
| Stochastic Oscillator | 23.52 | 57.98 |
Figure Technology Solutions Inc is building the future of capital markets with blockchain technology. proprietary technology powers next-generation lending, trading, and investing activities in areas such as consumer credit and digital assets. Its use of the blockchain ledger allows them to serve their end customers, improve speed and efficiency, and enhance standardization and liquidity. The Company operates as a single operating and reportable segment. The company's geographical operations is within the USA, with the majority of revenue from California.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.